Our flagship THP, glo
This innovative product comprises two main functional parts; an electronic handheld device that contains a lithium-ion battery which powers a heating chamber and a specially designed rod containing homogenised tobacco, called a Neostik, which is inserted into the device.
Everything has been designed so that nicotine and flavour are released through precision heating. The device is, in effect, a mini-oven designed to the highest specifications of thermophysical science.
The burning of a normal cigarette can reach over 900°C but the Neostik in our original glo device reaches around 245°C. This is sufficient to release nicotine, glycerol and flavourings via evaporation and distillation, but not high enough for combustion.
Let's take a closer look at glo pro.
glo pro uses induction heating and operates at a temperature of around 250°C on the standard profile. It also has a Boost Mode which enables the device to be ready for use in ten seconds.
Use the 360-technology to explore how glo pro works.
Ground-breaking results from our one-year clinical study of glo
We have published the full results from our one-year clinical study of our Tobacco Heating Product (THP), glo.
The results showed that smokers switching exclusively to glo achieved significant and sustained improvements in several indicators of potential harm associated with early disease development compared to smokers who continued to smoke. This included lung disease, cancer, and cardiovascular disease (CVD).
The data, published in Internal and Emergency Medicine3, build upon the favourable changes reported at three and six-months4. The improvements observed were sustained over the 12 months of the study, adding to the weight of evidence that supports glo as a less risky* alternative for adult smokers who would not otherwise quit.
Based on the early indicators of disease measured, smokers who switched completely to glo instead of continuing to smoke showed:
• Significant and sustained reduction in a biomarker with the potential to cause DNA damage associated with lung cancer
• Significant and sustained reduction in white blood cell count, an inflammatory marker associated with early development of CVD and other smoking-related diseases
• Sustained improvement in HDL cholesterol associated with reduced development of CVD
• Significant and sustained improvement in an indicator of lung health (FeNO)
• Significant and sustained improvement in a key indicator of oxidative stress, a process implicated in several smoking-related diseases, such as CVD
Read the full paper here.
Watch the video below to find out more about our clinical study.
Dr David O’Reilly, Director, Scientific Research at BAT, said: “The results from this study are the most important data we have ever generated about glo and for the THP category in general.
"This real-world study allows us to assess the changes that adult smokers switching exclusively to glo experience, by assessing early indicators of potential harm associated with disease development. It provides much needed new evidence about the size of the change and durability of the effect switching completely to glo can have, and reinforces glo’s potential as a reduced-risk product*.
“I’d like to thank everyone who participated in and helped deliver this study. It is another important step forward in our journey to building A Better Tomorrow.”